Advancement of PGx Testing: Development of Evidence-based Guidelines and the Ongoing Effort to Drive Alignment with Regulatory Bodies

Recorded on Wednesday, November 2nd, 2022 | AMP 2022

CPIC Co-PI and Director Dr. Kelly Caudle has been at the forefront of the changing landscape of pharmacogenomic testing. As the rapidly evolving science and supporting evidence have outpaced regulatory guidance, the medical community has looked to thought-leading organizations such as CPIC to translate the evidence of drug-gene interactions into actionable guidelines for care providers. In this workshop, Dr. Caudle will discuss the process and considerations behind CPIC guideline development and their ongoing work to continually evolve the list of drug-gene interactions recognized by the FDA. Attendees will gain insights into evidence-based guidelines and other resources to consider when developing and maintaining pharmacogenetic testing panels.

PRESENTED BY:

Kelly Caudle, PharmD, PhD

Kelly E. Caudle, Pharm.D., Ph.D., BCPS, Principal Investigator and Director, Clinical Pharmacogenetics Implementation Consortium (CPIC) 

Kelly E. Caudle, Pharm.D., Ph.D., BCPS is the Clinical Pharmacogenetics Implementation Consortium (CPIC) Principal Investigator and Director. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. To date, CPIC has published 26 gene-based clinical guidelines. Dr. Caudle oversees all CPIC-related projects and the CPIC guideline development process including the coordination of the guideline writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement. Furthermore, Dr. Caudle is involved in the clinical implementation of pharmacogenetics at St. Jude Children's Research Hospital.
 
Dr. Caudle received her Pharm.D. and Ph.D. from The University of Tennessee Health Science Center and completed an ASHP-accredited PGY2 residency at Le Bonheur Children’s Hospital. She is also a board‐certified Pharmacotherapy Specialist. Dr. Caudle is currently an affiliate Assistant Professor at The University of Tennessee Health Science Center.
More

Register Now

Register to reserve your seat for this workshop, or receive the workshop recording if you cannot attend.
Connect with Us
icon_img
Great news! If you missed our recent PGx webinar about predictive biomarker identification, you can view it on demand. Find out about the latest evidence supporting predictive biomarkers and how drug efficacy and safety are related to PGx variability. View the webinar now!
More
icon_img
The more touchpoints along a specimen's journey increase the chance for errors, especially with NGS workflow. Our sample identification solutions use single nucleotide polymorphism (SNPs) detection to provide a unique genetic fingerprint for each sample throughout the testing journey.
More

MORE FROM OUR VIDEO LIBRARY

AMP 2019 Workshop: Low Cost, High Sensitivity: The Advantages of MALDI-TOF for Liquid Biopsy & Solid Tumor Profiling
Video: The MassARRAY System by Agena Bioscience
Webinar Recording: Going beyond EGFR – Evaluating Technologies for Molecular Genetic Testing in NSCLC
Webinar Recording: Targeted Detection of MET and NTRK Oncogenic Variants in Routine Molecular Analysis

About Agena Bioscience

A global company with a mission to help laboratories translate genomic discoveries into targeted, cost-effective testing.

Connect

With exception of the MassARRAY Dx and MassARRAY SARS-CoV-2 Panel, all other products are For Research Use Only. Not for use in diagnostic procedures.
© 2022 Agena Bioscience